<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The results of a comparative clinical study with pentoxifylline -- a new vasoactive compound -- and xanthinol <z:chebi fb="2" ids="32544">nicotinate</z:chebi> in fifty-eight patients suffering from <z:hpo ids='HP_0005305'>cerebral thrombosis</z:hpo> with <z:hpo ids='HP_0002301'>hemiplegia</z:hpo> or monoplegia, are presented </plain></SENT>
<SENT sid="1" pm="."><plain>Pentoxifylline appeared to be more effective in reducing motor deficit and was significantly better in improving the patients' intelligence and memory score </plain></SENT>
<SENT sid="2" pm="."><plain>Recovery from speech deficit was equally well seen with both drugs </plain></SENT>
</text></document>